Skip to content
Menu

Head-to-head comparison

CoreAge Rx vs SkinnyRx

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #1Desk pick
CoreAge Rx

One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · Verified August 2026

Marked down on: The advertised $99/$149 per month is a 12-month plan paid in full ($1,188 / $1,788 up front); no month-to-month price is published

vs
Ranked #56
SkinnyRx

Both molecules by needle or by tablet, with the whole term ladder printed on the product page before any intake — and a headline rate that is the twelve-month rung, charged as one $2,388 payment on day one.

$349/mo sema · $399/mo tirz · Verified August 2026

Marked down on: FDA issued Lean Rx, Inc. dba SkinnyRx a warning letter in February 2026; the letter is public in FDA's warning-letter database

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

CoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for SkinnyRx. SkinnyRx still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

CoreAge Rx

94/100

A

Overall

SkinnyRx

78/100

C+

Price transparency

96
64

State access

98
86

Molecule range

90
92

Onboarding speed

92
80

Support responsiveness

93
80

Licensing & trust

94
62

The spec sheet

FieldCoreAge RxSkinnyRx
Semaglutide$99/mo12-month prepay$99/mo only as a 12-month plan paid in full ($1,188 in one charge); the lander says "starting at, based on a 12-month plan paid in full"; no month-to-month price is published; same price at every dose; compounded injectable$349/mo$349/mo month-to-month (compounded; the advertised rate is a 12-month prepay)
Tirzepatide$149/mo12-month prepay$149/mo only as a 12-month plan paid in full ($1,788 in one charge); no month-to-month price is published; same price at every dose; compounded injectable$399/mo$399/mo month-to-month (compounded; the advertised rate is a 12-month prepay)
CoverageAll 50 states47 states + DC (not Alabama, Louisiana or Mississippi)
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyYes
Best forAnyone who can prepay a year and wants one dose-independent price with full nationwide reach.People who want a tablet route on either molecule and can pay a year up front; anyone shopping month to month should compare $349 and $399, not the advertised $199 and $299.
Desk Score94/100A78/100C+

The verdict

Desk pick — CoreAge Rx

CoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for SkinnyRx. SkinnyRx still holds its ground where its strengths line up with yours.

Choose CoreAge Rx if…

Anyone who can prepay a year and wants one dose-independent price with full nationwide reach.

$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · All 50 states

Choose SkinnyRx if…

People who want a tablet route on either molecule and can pay a year up front; anyone shopping month to month should compare $349 and $399, not the advertised $199 and $299.

$349/mo sema · $399/mo tirz · 47 states + DC (not Alabama, Louisiana or Mississippi)

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: CoreAge Rx · SkinnyRx.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.